Literature DB >> 12025229

Intracellular flow cytometric analysis of primary cultured breast tumor cells.

Ruth L Loveday1, Valerie Speirs, Philip J Drew, Michael J Kerin, John R T Monson, John Greenman.   

Abstract

Cell lines are traditionally used as tools for in vitro studies of breast cancer. It is highly debatable however, because of the genetic drift that occurs in such long term cultures how representative these cell lines are of breast cancer in vivo. For this reason primary cultures are generally regarded as a better model. Here we have used a primary culture technique (Int. J. Cancer, 66 (1996) 551; Br. J. Cancer, 78 (1998) 1421) to obtain primary breast cancer cells from 13 breast cancer biopsies. We then describe the development and use of methodology to confirm the purity of the cultures. The acquisition of a highly pure population of epithelial cells was confirmed by flow cytometric analysis of intracellular vimentin and cytokeratin 19. The methodology described will have many applications in studies requiring a highly pure population of epithelial breast cancer cells, as well as wide use in other cancers.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12025229     DOI: 10.1081/cnv-120001179

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  3 in total

1.  Characterization of ductal carcinoma in situ cell lines established from breast tumor of a Singapore Chinese patient.

Authors:  Jacklyn Wy Yong; Meng Ling Choong; SiFang Wang; Yu Wang; Shermaine Qy Lim; May Ann Lee
Journal:  Cancer Cell Int       Date:  2014-09-20       Impact factor: 5.722

2.  Characterization of human breast cancer epithelial cells (HBCEC) derived from long term cultured biopsies.

Authors:  Ralf Hass; Catharina Bertram
Journal:  J Exp Clin Cancer Res       Date:  2009-09-14

Review 3.  Breast cancer cell lines: friend or foe?

Authors:  Sarah E Burdall; Andrew M Hanby; Mark R J Lansdown; Valerie Speirs
Journal:  Breast Cancer Res       Date:  2003-02-03       Impact factor: 6.466

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.